Background
Monsanto Company had developed and patented genetically modified soybeans engineered to be resistant to its Roundup (glyphosate) herbicide — marketed as “Roundup Ready” seed. The modification allowed farmers to spray Roundup broadly over their fields to kill weeds without harming the crops, dramatically reducing weed-control costs. Monsanto held U.S. Patents 5,633,435 and 5,352,605 covering the glyphosate-tolerant plants, the modified seeds, and the method of producing them.
Monsanto sold Roundup Ready seed to farmers subject to a Technology Agreement that required: (1) the seed be used to plant a single commercial crop only; (2) the farmer not save any crop produced from the seed for replanting; and (3) the farmer not supply saved seed to anyone for replanting. Homan McFarling, a Missouri farmer, purchased Roundup Ready seed and signed the Technology Agreement. He then saved 1,500 bushels of his harvest in one season and planted those saved seeds the following season, repeating the process again the year after. He paid no additional license fees for the saved seeds.
Monsanto sued McFarling for patent infringement. McFarling argued that the patent exhaustion doctrine — the first sale doctrine — had extinguished Monsanto’s patent rights when Monsanto sold him the seed. The district court entered a preliminary injunction against McFarling and he appealed.
The Court’s Holding
The Federal Circuit affirmed the preliminary injunction and held that McFarling’s saved-seed planting infringed Monsanto’s patents. The court rejected the patent exhaustion defense on straightforward grounds: the doctrine of exhaustion applies to patented articles that have actually been sold by the patentee, not to articles made by copying a patented article. The seeds McFarling replanted were not seeds that Monsanto had sold him — they were new seeds that McFarling had grown and harvested himself from his crop. These new seeds had never been sold by Monsanto and therefore Monsanto’s patent rights in them had never been exhausted.
The court also addressed the license restriction. McFarling argued that the Technology Agreement’s prohibition on saving seed was an unlawful extension of patent rights beyond the scope of the patent grant. The court disagreed, holding that the restrictions in the agreement were well within Monsanto’s patent grant, which covered the seeds themselves. By restricting the farmer to a single season’s use, Monsanto was simply delineating the scope of the license it was granting — something any patentee can do. There was no unlawful tying arrangement or misuse.
Key Takeaways
- The patent exhaustion doctrine applies only to patented articles that were actually sold by the patentee — it does not exhaust rights in articles made by copying a purchased item.
- Farmers who purchase patented seed under a single-use license and then save and replant offspring seed infringe the patent because the offspring seed was never sold by the patentee.
- Patentees may impose single-use restrictions in license agreements for self-replicating technologies without engaging in patent misuse.
- The court treated seed-saving as analogous to making unauthorized copies of a patented article, rather than as a natural consequence of using a purchased product.
- This decision was a major win for agricultural biotechnology companies’ business models and set the stage for the Supreme Court’s later Bowman v. Monsanto decision (2013).
Why It Matters
Monsanto v. McFarling was the foundational Federal Circuit ruling on whether the patent exhaustion doctrine could limit biotechnology companies’ control over self-replicating patented seeds. By holding that exhaustion does not apply to seeds grown from purchased patented seed (as opposed to the seeds actually purchased), the court validated the annual-licensing model that has become standard in the agricultural biotechnology industry. Farmers must purchase new seed every year rather than saving seed from their harvest.
The decision shaped the entire commercial structure of the GM crop industry. It also ignited significant controversy about the tension between patent law and traditional farming practices, in which seed-saving has been a cornerstone for millennia. The legal framework established in McFarling was affirmed by the Supreme Court in Bowman v. Monsanto Co. (2013), which unanimously held that patent exhaustion does not permit a purchaser to make new copies of a patented article — even through a natural process of plant reproduction.